Evidence-based guidelines to optimize the selection of antibody panels in cytopathology: Pleural effusions with malignant epithelioid cells

Diagnostic Cytopathology

Volumn 38, Issue 1, 2010, Pages 9-14

  Westfall, Danielle E ^a   Fan, Xuemo ^a   Marchevsky, Alberto M ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Antibody panel; Evidence based medicine; Immunohistochemistry; Pleural fluid

Indexed keywords

ANTIBODY; CA 125 ANTIGEN; CALRETININ; ESTROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR CDX2;

ANTIBODY SCREENING; ARTICLE; BAYES THEOREM; BREAST CARCINOMA; CARCINOMA CELL; CLINICAL ARTICLE; COLON CARCINOMA; CYTOPATHOLOGY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; LUNG CARCINOMA; MALE; MESOTHELIOMA; MESOTHELIUM CELL; MIXED MULLERIAN TUMOR; PLEURA EFFUSION; PLEURA FLUID; PRIORITY JOURNAL; PROSTATE CARCINOMA; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STOMACH CARCINOMA; SYSTEMATIC REVIEW;

ANTIBODIES; EPITHELIOID CELLS; EVIDENCE-BASED MEDICINE; FEMALE; GUIDELINES AS TOPIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; PLEURAL EFFUSION; PLEURAL NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 72149101492     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21146     Document Type: Article

References (11)

1. Marchevsky AM. Evidence-based medicine in pathology: An introduction. Semin Diagn Pathol 2005;22:105-115.
2. Marchevsky AM. The application of special technologies in anatomic pathology: Is it consistent with the Principles of Evidence- Based Medicine? Semin Diagn Pathol 2005;22:156-166.
3. Ascoli V, Taccogna S, Scalzo CC, et al. Utility of cytokeratin 20 in identifying the origin of metastatic carcinomas in effusions. Diagn Cytopathol 1995;12:303-308.
4. Frisman DM, McCarthy WF, Schleiff P, et al. Immunocytochemistry in the differential diagnosis of effusions: Use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations. Mod Pathol 1993;6:179-184.
5. Garcia MT, Maleki Z, Gomez-Fernandez, et al. Use of a limited immunocytochemical panel in classification of malignant pleural effusions in women. Mod Pathol 2008;21:75A.
6. Gomez-Fernandez C, Jorda M, Delgado PI, et al. Thyroid transcription factor 1: A marker for lung adenocarcinoma in body cavity fluids. Cancer 2002;96:289-293. (Pubitemid 35221616)
7. Pomjanski N, Grote HJ, Doganay P, et al. Immunocytochemical identification of carcinomas of unknown primary in serous effusions. Diagn Cytopathol 2005;33:309-315. (Pubitemid 41598050)
8. Porcel JM, Vives M, Esquerda A, et al. Use of a panel of tumor markers in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 2004;126:1721-1722.
9. Saad , Linder RS, Lin JL, et al. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement. Diagn Cytopathol 2006;34:801-806.
10. Yaziji H, Battifora H, Barry TS, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: Identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 2006;19: 514-523.
11. Marchevsky AM, Wick MR. Evidence-based guidelines for the utilization of immunostains in diagnostic pathology: Pulmonary adenocarcinoma versus mesothelioma. Appl Immunohistochem Mol Morphol 2006;00:1-6.